ReLive is a pioneering global biotechnology company, founded in 2021 by a team of distinguished visionaries and accomplished experts in the fields of tissue engineering, regenerative medicine, and cell therapy. Backed by venture capital, along with the acquisition of CO.DON, ReLive brings together a diverse team of scientists, surgeons, managers and regulatory experts with extensive and direct experience in biotechnology, to collaborate and develop groundbreaking treatments that improve patient outcomes. Through our ongoing research and development efforts, we strive to make a lasting impact on the field of biotechnology and cell therapy and revolutionize the treatment of or theopoetic and reconstructive conditions.